MELISSA MALINOSKI: Open Payments
NPI 1366814931 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$43,186 in 243 payments from 14 companies in 2025. Trend: 2023 $12,859 · 2024 $21,050 · 2025 $43,186
Speaker / faculty: $28,500Consulting: $6,898Food & beverage: $4,698Travel & lodging: $2,986Education: $104
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 59 | $23,093 |
| Alkermes, Inc. | 39 | $9,098 |
| ABBVIE INC. | 48 | $8,866 |
| Neurocrine BioSciences, Inc. | 33 | $722 |
| Otsuka America Pharmaceutical, Inc. | 20 | $497 |
| Teva Pharmaceuticals USA, Inc. | 18 | $463 |
| Supernus Pharmaceuticals, Inc. | 14 | $164 |
| Inspire Medical Systems, Inc. | 1 | $92 |
| Indivior Inc. | 4 | $67 |
| Braeburn Inc. | 3 | $55 |
Products named: CAPLYTA, VRAYLAR, LYBALVI, INGREZZA, REXULTI, AUSTEDO XR, ARISTADA, Qelbree.
Industry payments across MI — which companies pay providers there.
